ADVANCES IN NETWORK PHARMACOLOGY FOR CANCER THERAPY: INTEGRATING TUMOR BIOLOGY, SYSTEMS BIOLOGY, AND PRECISION MEDICINE
TL;DR
Network pharmacology provides a systems-level framework integrating multi-omics and tools like STRING and Cytoscape to overcome the limitations of single-target cancer therapies.
Problem / question
Conventional one drug-one target cancer therapies frequently fail due to tumor heterogeneity, compensatory signaling mechanisms, and drug resistance within complex biological networks.
Methods
The authors review systems biology and network science approaches, highlighting the integration of genomics, proteomics, and metabolomics using bioinformatics resources such as STRING, KEGG, Cytoscape, and TCGA.
Key findings
The review identifies that analyzing protein-protein interaction and gene regulatory networks is essential for understanding cancer pathogenesis. It highlights that network pharmacology facilitates multi-target drug discovery and the optimization of combination therapies, addressing the dynamic interactions among genes, proteins, and the tumor microenvironment that drive treatment failure.
Why it matters
This approach provides a comprehensive framework to decipher cancer complexity, accelerating the development of personalized and more effective anticancer therapies.
Limitations
The field faces ongoing challenges related to data integration, standardization, and the experimental validation of computational network models.
Takeaway
By treating cancer as a network disease and utilizing tools like KEGG and Cytoscape, researchers can design multi-target therapies that overcome the resistance mechanisms of traditional single-target drugs.